A Phase 4 interventional study of Cilostazol and Aspirin in Cerebral Infarction, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-06-10.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cilostazol in Cerebral Infarction — 1 open to participants now, 1 under way, none of them phase 3. Cilostazol · Cerebral Infarction.
Among the 10 studies testing cilostazol in Cerebral Infarction, this one has the largest enrollment, is the only one that started in 2003, is one of 8 in phase 4, and was the 3rd registered.
219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.
Browse Cerebral Infarction studies →1 of the 10 studies testing cilostazol in Cerebral Infarction is open now, in 1 country. Recruiting first, the newest first:
Asan Medical Center · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →
Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,800 is above the median of 120 across 139 interventional studies indexed under Cerebral Infarction.
Median enrollment 594 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 7 studies filed under Cerebral Infarction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cilostazol in Cerebral Infarction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg, once daily).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cilostazol
Drug: Cilostazol
Aspirin
Drug: Aspirin
oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
Numbers of Patients With First Occurence of Stroke
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])
Number of Patients With First Recurrence of Cerebral Infarction
Time frame: From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Number of Deaths From Any Cause
Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Number of Patients With First Occurrence of Haemorrhagic Event
The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
Time frame: From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])
Patients with non-cardioembolic ischemic stroke have been recruited at 278 study sites in Japan between December, 2003, and October, 2006.
| Milestone | Cilostazol | Aspirin |
|---|---|---|
| Started | 1356 | 1360 |
| Completed | 881 | 1004 |
| Not completed | 475 | 356 |
| Withdrew: Adverse event | 268 | 166 |
| Withdrew: Withdrawal by subject | 73 | 56 |
| Withdrew: Physician decision | 23 | 22 |
| Withdrew: Not classified | 111 | 112 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
| participants | Cilostazol | Aspirin |
|---|---|---|
| Numbers of Patients With First Occurence of Stroke | 82 | 119 |
| participants | Cilostazol | Aspirin |
|---|---|---|
| Number of Patients With First Recurrence of Cerebral Infarction | 72 | 88 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
| participants | Cilostazol | Aspirin |
|---|---|---|
| Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease | 86 | 103 |
Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
| participants | Cilostazol | Aspirin |
|---|---|---|
| Number of Deaths From Any Cause | 13 | 13 |
The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
| participants | Cilostazol | Aspirin |
|---|---|---|
| Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events | 138 | 186 |
The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.
| participants | Cilostazol | Aspirin |
|---|---|---|
| Number of Patients With First Occurrence of Haemorrhagic Event | 23 | 57 |
Collected over From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cilostazol | — | 372/1,337 (27.8%) | 1,267/1,337 (94.8%) |
| Aspirin | — | 433/1,335 (32.4%) | 1,260/1,335 (94.4%) |
| Event | Cilostazol | Aspirin |
|---|---|---|
| Cerebral infarctionNervous system disorders | 62/1337 | 84/1335 |
| Cerebral haemorrhageNervous system disorders | 4/1337 | 25/1335 |
| CataractEye disorders | 22/1337 | 17/1335 |
| Inguinal herniaGastrointestinal disorders | 11/1337 | 5/1335 |
| Myocardial infarctionCardiac disorders | 10/1337 | 3/1335 |
| Colonic polypGastrointestinal disorders | 10/1337 | 7/1335 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/1337 | 9/1335 |
| PneumoniaInfections and infestations | 8/1337 | 9/1335 |
| Transient ischaemic attackNervous system disorders | 8/1337 | 9/1335 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/1337 | 8/1335 |
| Event | Cilostazol | Aspirin |
|---|---|---|
| NasopharyngitisInfections and infestations | 546/1337 | 590/1335 |
| HeadacheNervous system disorders | 312/1337 | 217/1335 |
| HypertensionVascular disorders | 120/1337 | 185/1335 |
| Back painMusculoskeletal and connective tissue disorders | 160/1337 | 165/1335 |
| DiarrhoeaGastrointestinal disorders | 164/1337 | 85/1335 |
| PalpitationsCardiac disorders | 156/1337 | 71/1335 |
| ConstipationGastrointestinal disorders | 110/1337 | 155/1335 |
| ContusionInjury, poisoning and procedural complications | 128/1337 | 121/1335 |
| DizzinessNervous system disorders | 124/1337 | 92/1335 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 118/1337 | 102/1335 |
| Age, Categorical(Participants) | Cilostazol | Aspirin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 681 | 685 | 1366 |
| >=65 years | 656 | 650 | 1306 |
| Age Continuous(years) | Cilostazol | Aspirin | Total |
|---|---|---|---|
| Mean | 63.5 ± 9.2 | 63.4 ± 9.0 | 63.4 ± 9.1 |
| Sex: Female, Male(Participants) | Cilostazol | Aspirin | Total |
|---|---|---|---|
| Female | 378 | 378 | 756 |
| Male | 959 | 957 | 1916 |
| Region of Enrollment(participants) | Cilostazol | Aspirin | Total |
|---|---|---|---|
| Japan | 1337 | 1335 | 2672 |
The record gives a start of Dec 2003, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilostazol
Otsuka Pharmaceutical Co., Ltd. →